The Antibody Society Webinars

 

The Antibody Society hosts webinars on a variety of topics that relate to the research and development of antibodies.

Antibodies to Watch webinars provide timely updates on events related to antibody therapeutics in late-stage development and regulatory review, and those that were recently approved.

 

The On Demand webinars #1-10 comprise our Antibody Validation Webinar Series, which is hosted by Dr. Simon Goodman and aimed especially at those beginning a career in biological sciences. In this series, leaders in antibody research from industry and academia reflect on antibody validation.

Webinars
Collapse Antibodies to Watch in 2021 (Webinar)

The COVID-19 pandemic has presented many challenges to the biopharmaceutical industry. Initiating programs to discover and develop new antibodies that targeted SARS-CoV-2 was critical, but at the same time, programs bringing existing investigational therapies through late-stage clinical studies and regulatory review also needed to be maintained.

Dr. Janice Reichert (The Antibody Society) will provide an update on antibody therapeutics approved in the US and European Union during 2020, those that may be approved by the end of 2021, and those that might enter regulatory review in the US or EU soon. She will also discuss current and potential emergency use authorizations for anti-SARS-CoV-2 antibodies.

Dr. Nick Hutchinson (FUJIFILM Diosynth Biotechnologies) will discuss how the pandemic has driven scientists and engineers to find new ways to leverage antibody production capacity most effectively in order to meet the need for rapid early phase development, as well as high-demand commercial manufacturing and what this may mean for antibody manufacturing strategies in the future.

Formats Available: Live Webcast
Original Seminar Date: December 03, 2020
Register HereRegister Here Antibodies to Watch in 2021 (Webinar)
On-Demand
Collapse Antibodies to Watch in a Pandemic (On Demand)

The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe have mobilized teams to research the SARS-CoV-2 virus and COVID-19, conduct clinical studies of repurposed biologics, and research and develop anti-SARS-CoV-2 biologics. Disruptions at companies and regulatory agencies, however, have raised concerns about the effects of the pandemic on possible approvals of non-COVID-19 antibody therapeutics. In a series of webinars, The Antibody Society will report on important developments in the commercial pipeline of antibody therapeutics for COVID-19, as well as other indications.

In “Antibodies to Watch in a Pandemic”, Dr. Janice Reichert (The Antibody Society) provides an update on non-COVID-19 antibody therapeutics approved in the first half of 2020, and those that might be approved by the end of the year. She also discusses the ~ 130 biologics currently in development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics. Additionally, Dr. Thomas Schirrmann (Yumab) presents a case study of how to develop anti-SARS-CoV-2 antibodies in both academic and industrial settings.

Formats Available: Streaming
Original Seminar Date: June 30, 2020
On-Demand Release Date: Available Now
Register HereRegister Here Antibodies to Watch in a Pandemic (On Demand)
Collapse #1 - Antibody specificity? What
The Antibody Society's Webcast series on Antibody Validation

In this introduction to the topic, Professor Andreas Plückthun, University of Zürich, discusses the biology of the 3 principal types of commercial antibodies: polyclonal, monoclonal, and recombinant.  Surprisingly, only recombinants offer a reasonable hope of reproducibility in the long term – yet they remain very much the minority.

Formats Available: On Demand
Original Seminar Date: November 12, 2019
Register HereRegister Here #1 - Antibody specificity? What
Collapse #2 - Antibodies drive irreproducibility (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Professor Glenn Begley, Biocurate Pty Ltd, and Professor Cecilia Williams, KTH  Royal Institute of Technology, describe arduous, alarming and very costly experiences in failing to confirm “well established” critical data in oncology –a failure often driven by ineptly characterized antibodies.

Formats Available: On Demand
Original Seminar Date: November 13, 2019
Register HereRegister Here #2 - Antibodies drive irreproducibility (On-Demand)
Collapse #3 - What
The Antibody Society's Webcast series on Antibody Validation

Dr. Jan Voskuil, Aeonian Biotech, and Professor Andy Chalmers, University of Bath and CiteAb, delve into the mysterious world of original equipment manufacturers (OEMs), which can veil the identity of antibodies, and data-base repositories that help unveil which antibody has produced reliable results.

Formats Available: On Demand
Original Seminar Date: December 04, 2019
Register HereRegister Here #3 - What
Collapse #4 - What is this Antibody? (On-demand)
The Antibody Society's Webcast series on Antibody Validation

Professor Anita Bandrowski, University California San Diego and SciCrunch, and Dr. Jan Voskuil, Aeonian Biotech, probe how antibody reagents are identified.  If we can’t identify which antibody has been used, we can never reproduce experiments.  The Research Reagent Identifier systematically tags antibodies so they can be tracked, but the small-print on the data-sheets still hides many things.

Formats Available: On Demand
Original Seminar Date: December 05, 2019
Register HereRegister Here #4 - What is this Antibody? (On-demand)
Collapse #5 - Really? Out of control(s)? (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Giovanna Roncador, Centro Nacional de Investigaciones Oncológicas and EuroMabNet, examinesthe criticality ofusing appropriate fit-for-purpose controls, both positive and negative, to validate antibodies in every experimental context.

Formats Available: On Demand
Original Seminar Date: January 15, 2020
Register HereRegister Here #5 - Really? Out of control(s)? (On-Demand)
Collapse #6 - Even the easy stuff isn
The Antibody Society's Webcast series on Antibody Validation

Professors Aldrin Gomes and James Trimmer, both from University of California, Davis, dissect two “basic” validation technologies, Western blot and immunohistochemistry, to expose the very many things that can distort validation data.

Formats Available: On Demand
Original Seminar Date: January 22, 2020
Register HereRegister Here #6 - Even the easy stuff isn
Collapse #7 - It
The Antibody Society's Webcast series on Antibody Validation

Dr. Travis Hardcastle, Horizon, and Dr. Alejandra Solache, Abcam, describe the character of different gene-knockout technologies, one of the strongest validation technologies, and their value in large-scale antibody screening. 

Formats Available: On Demand
Original Seminar Date: January 29, 2020
Register HereRegister Here #7 - It
Collapse #8 - Protein Arrays and Mass Spectrometry (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Mike Taussig, Cambridge Protein Arrays, and Dr. Fridtjof Lund-Johansen, Oslo University Hospital, look at array and immunoprecipitation-mass spectrometry technologies, which offer a broader and deeper image of antibody specificity and selectivity for validation, than classical validation technologies.

Formats Available: On Demand
Original Seminar Date: February 05, 2020
Register HereRegister Here #8 - Protein Arrays and Mass Spectrometry (On-Demand)
Collapse  #9 - Getting to Recombinant Antibodies that Guarantee Reproducible Research (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Andrew Bradbury, Specifica, suggests ways out of the validation maze by rigorous molecular identification of recombinant tool antibodies. This achievable goal could eliminate many of the shadowy issues described in this series of webinars.

Formats Available: On Demand
Original Seminar Date: February 12, 2020
Register HereRegister Here  #9 - Getting to Recombinant Antibodies that Guarantee Reproducible Research (On-Demand)
Collapse #10 - Specific Detection Reagents: What
The Antibody Society's Webcast series on Antibody Validation

Future recombinant binding tools may avoid antibodies, and use diversified libraries based on small and versatile protein scaffolds, for example the DARPins (Designed Ankyrin Repeat Proteins).  DARPins are single-chain, monodisperse, and non-immunogenic, and can be made rapidly and cheaply in bacteria in many formats.  They can also be expressed in and on cells as non-aggregating fusion proteins with tunable valencies, which opens a wide range of previously inaccessible approaches in cell biology and biochemistry.

Formats Available: On Demand
Original Seminar Date: February 19, 2020
Register HereRegister Here #10 - Specific Detection Reagents: What